Clinical characteristics and treatment outcome of Candida tracheobronchitis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
12 Feb 2021
12 Feb 2021
Historique:
received:
28
08
2020
accepted:
07
01
2021
entrez:
13
2
2021
pubmed:
14
2
2021
medline:
24
2
2021
Statut:
ppublish
Résumé
Although Candida species can cause invasive fungal diseases, such as disseminated infection and pneumonia, they rarely cause tracheobronchitis, which is often fatal.To identify the clinical characteristics of Candida tracheobronchitis, we retrospectively evaluated 8 patients who had pathologically proven Candida tracheobronchitis.Their median age was 64 (range: 51-70) years and 5 were females. Three patients had solid cancers and 5 had hematological malignancies. We classified tracheobronchitis into localized and diffuse types. Of the 8 patients, 5 had localized and 3 had diffuse tracheobronchitis. While all patients with diffuse tracheobronchitis had predisposing risk factors for invasive fungal disease, such as prolonged corticosteroid use, recent use of nucleoside analogues, or recent neutropenia (<500/m3), only 2 of the 5 with localized tracheobronchitis had predisposing risk factors. Four of the 5 patients with localized tracheobronchitis had loco-regional bronchial mucosal damage (e.g., radiation or photodynamic therapy). Although all 8 patients ultimately died, some improved with or without antifungal treatment. Two of the 5 patients (1 with localized and the other with diffuse tracheobronchitis) who received antifungal agents improved after treatment, and 1 patient with localized tracheobronchitis who did not receive antifungal treatment improved spontaneously. Two of the 3 patients with diffuse tracheobronchitis did not respond to antifungal treatment.Candida tracheobronchitis can present as both localized and diffuse types. While the former was influenced more by loco-regional mucosal damage, the latter was influenced more by the patient's immune status. The treatment outcomes were especially poor in patients with diffuse tracheobronchitis.
Identifiants
pubmed: 33578566
doi: 10.1097/MD.0000000000024606
pii: 00005792-202102120-00059
pmc: PMC7886430
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24606Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interests to disclose.
Références
Adiguzel N, Karakurt Z, Gungor G, et al. Mortality rates and risk factors associated with nosocomial Candida infection in a respiratory intensive care unit. Tuberk Toraks 2010;58:35–43.
Grossi P, Farina C, Fiocchi R, et al. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000;70:112–6.
Garnacho-Montero J, Olaechea P, Alvarez-Lerma F, et al. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient. Rev Esp Quimioter 2013;26:173–88.
Lin CY, Liu WL, Chang CC, et al. Invasive fungal tracheobronchitis in mechanically ventilated critically ill patients: underlying conditions, diagnosis, and outcomes. Ann Intensive Care 2017;7:9.
Karnak D, Avery RK, Gildea TR, et al. Endobronchial fungal disease: an under-recognized entity. Respiration 2007;74:88–104.
Pendleton KM, Huffnagle GB, Dickson RP. The significance of Candida in the human respiratory tract: our evolving understanding. Pathog Dis 2017;75.
Kontoyiannis DP, Reddy BT, Torres HA, et al. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis 2002;34:400–3.
De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–21.
Franquet T, Muller NL, Oikonomou A, et al. Aspergillus infection of the airways: computed tomography and pathologic findings. J Comput Assist Tomogr 2004;28:10–6.
Kang EY. Large airway diseases. J Thorac Imaging 2011;26:249–62.
Valentine JC, Morrissey CO, Tacey MA, et al. A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005–2016. BMC Infect Dis 2019;19:274.
Tanaka K, Goto H, Tsubakihara M, et al. Candidal tracheobronchitis in poorly controlled diabetes mellitus. Intern Med 2017;56:121–2.
Takaki M, Tanaka T, Matsui K, et al. Candidal tracheobronchitis after total aortic replacement and thoracic endovascular aortic repair. Respirology 2018;23:306–7.
Schaenman JM, Rosso F, Austin JM, et al. Trends in invasive disease due to Candida species following heart and lung transplantation. Transpl Infect Dis 2009;11:112–21.
Hosseini-Moghaddam SM, Husain S. Fungi and molds following lung transplantation. Semin Respir Crit Care Med 2010;31:222–33.
Nunley DR, Gal AA, Vega JD, et al. Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation. Chest 2002;122:1185–91.
Khan AH, Tandon R. Candida tracheobronchitis: a case report of a rare disease. Am J Resp Crit Care Med 2016;193:A1875.
Spear RK, Walker PD, Lampton LM. Tracheal obstruction associated with a fungus ball. A case of primary tracheal candidiasis. Chest 1976;70:662–3.
Clarke A, Skelton J, Fraser RS. Fungal tracheobronchitis. Report of 9 cases and review of the literature. Medicine (Baltimore) 1991;70:1–4.
Terraneo S, Ferrer M, Martin-Loeches I, et al. Impact of Candida spp. isolation in the respiratory tract in patients with intensive care unit-acquired pneumonia. Clin Microbiol Infect 2016;22:94e91-94 e98.